Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
05 nov. 2024 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
18 sept. 2024 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
04 déc. 2023 08h00 HE
|
Vaccinex, Inc.
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ...
KEYTRUDA Drug Insight and Market Forecast Report, 2019-2022 & 2023-2032: Focus on 7 Major Markets - United States, Germany, France, Italy, Spain, United Kingdom, and Japan
27 nov. 2023 10h03 HE
|
Research and Markets
Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The "KEYTRUDA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 08h00 HE
|
Vaccinex, Inc.
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...
Vaccinex Announces Pricing of $9.6 Million Public Offering
28 sept. 2023 21h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
26 sept. 2023 08h00 HE
|
Vaccinex, Inc.
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease...
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
31 août 2023 07h32 HE
|
Adagene Inc.
- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy – -...
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients
27 avr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
30 mars 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...